Tumor therapy with alphavirus-based and high affinity...

Details Tumor therapy with alphavirus-based and high affinity... Tumor therapy with alphavirus-based and high affinity...

2007-12-11

2007-12-11

Schnizer, Richard (Department: 1635)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093600, C424S093100, C435S456000

Reexamination Certificate

active

10473477

ABSTRACT:
The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to Sindbis virus vectors which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis.

REFERENCES:
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5739026 (1998-04-01), Garoff
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5814482 (1998-09-01), Dubensky et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 6015686 (2000-01-01), Dubensky, Jr. et al.
patent: 6015694 (2000-01-01), Dubensky, Jr. et al.
patent: 6190666 (2001-02-01), Garoff et al.
patent: 6224879 (2001-05-01), Sjoberg
patent: 6242259 (2001-06-01), Polo et al.
patent: 6329201 (2001-12-01), Polo et al.
patent: 6342372 (2002-01-01), Dubensky, Jr. et al.
patent: 6376236 (2002-04-01), Dubensky, Jr. et al.
patent: 6391632 (2002-05-01), Dubensky, Jr. et al.
patent: 6426196 (2002-07-01), Dubensky, Jr. et al.
patent: 6451592 (2002-09-01), Dubensky, Jr. et al.
patent: 6458560 (2002-10-01), Dubensky, Jr. et al.
patent: 6465634 (2002-10-01), Dubensky, Jr. et al.
patent: 6566093 (2003-05-01), Liljestrom et al.
patent: 6592874 (2003-07-01), Schlesinger et al.
patent: 6692750 (2004-02-01), Sjoberg et al.
patent: 6730297 (2004-05-01), Davidson et al.
patent: 6770283 (2004-08-01), Garoff et al.
patent: WO-99/18226 (1999-04-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/44423 (1999-09-01), None
patent: WO-99/44423 (1999-09-01), None
Smerdou et al (J. Virol. 73: 1092-1098, 1999).
Asselin-Paturel et al (Gene Therapy 5: 606-615, 1998).
Zhang et al (Gene Therapy 4: 367-374, 1997).
Leitner et al (Cancer Research 60: 51-55, 2000).
Murphy et al (Gene Therapy 7: 1477-1482, 2000).
Miller et al. (FASEB J. 9: 190-199, 1995).
Deonarain (Exp. Opin. Ther. Patents 8(1):53-69, 1998).
Verma et al (Nature 389: 239-242, 1997).
Crystal (Science 270: 404-410, 1995).
Pouton et al (Adv. Drug Del. Rev. 46: 187-203, 2001).
Read et al (Adv. Gen. 53:19-46, 2005).
Higashikawa et al (Virology 280: 124-131, 2001).
De Polo et al, J. Virol. 73 :6708-6714, 1999).
Alemany et al (J. Gen. Virol 81: 2605-2609, 2000).
Sung et al. Mol. Ther. 3: 757-767, 2001).
Unno et al (Clin. Cancer Res. 11(12): 4553-4560, 2005).
Frolov (J. Virol. 68(3): 1721-1727, 1994).
Perri et al (J. Virol. 74(20): 9802-9807, 2000).
Karpf et al (Virology 240: 193-201, 1998).
Tseng et al (Nature Biotechnolgy 22(1): 70-77, 2004).
Lundstrom (Gene Therapy 12: S92-S97, 2005).
Klimp et al, “Activation of Peritoneal Cells Upon In Vivo Transfection with a Recombinant Alphavirus Expressing GM-CSF,”Gene Therapy, Feb. 2000, vol. 8, No. 4, pp. 300-307.
Leitner et al, “Enhancement of Tumor-specific Immune Response with Plasmid DNA Replicon Vectors,”Cancer Research, Jan. 1, 2000, vol. 60, No. 1, pp. 51-55.
Li et al., “Rescue of Sindbis Virus-Specific RNA Replication and Transcription by Using a Vaccinia Virus Recombinant,”Journal of Virology, Dec. 1991, vol. 65, No. 12, pp. 6714-6723.
Cheng et al, “Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22-Antigen Fusion,”Human Gene Therapy, Mar. 1, 2002, vol. 13, No. 4, pp. 553-568.
Velders et al., “Eradication of Established Tumors of Vaccination with Venezuelan Equine Encephalitis Virus Replicon Particles Delivering Human Papillomavirus 16 E7 RNA,”Cancer Research, Nov. 1, 2001, vol. 61, No. 21, pp. 7861-7867.
Perri, Slyvia et al. “Replicon Vectors Derived from Sindbis Virus and Semliki Forest Virus That Establish Persistent Replication in Host Cells.” Journal of Virology, Oct. 2000, pp. 9802-9807, vol. 74, No. 20.
Ying H. et al., “Cancer Therapy Using a Self-Replicating RNA Vaccine”, Nature Medicine, Jul. 1999, pp. 823-827, vol. 5, No. 7, Nature Publishing Group, New York, USA.
Schlesinger S. et al., “Alphavirus Vectors for Gene Expression and Vaccines”, Current Opinion in Biotechnology, Oct. 1999, pp. 434-439, vol. 10, No. 5, London, GB.

Affiliated with

Also associated with

Rating

Tumor therapy with alphavirus-based and high affinity... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor therapy with alphavirus-based and high affinity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor therapy with alphavirus-based and high affinity... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3895894